-
公开(公告)号：US11472881B2
公开(公告)日：2022-10-18
申请号：US16341034
申请日：2017-10-10
发明人： Yafeng Zhang , Shu Wu , Shuai Yang , Chuan-Chu Chou
摘要： The present application provides constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Also provided are methods of making and using these constructs.
-
公开(公告)号：US20220144960A1
公开(公告)日：2022-05-12
申请号：US17312497
申请日：2019-12-26
发明人： Shuai Yang , Sujuan Wang , Chenyu Shu , Yuanyuan Peng , Chen Hu , Shu Wu
IPC分类号： C07K16/28 , A61K35/17 , A61P35/00 , C07K14/725 , C12N5/0783
摘要： CD30-binding moieties, chimeric antigen receptors (CARs) having these CD30-binding moieties, and uses thereof are provided. Polynucleotides encoding the CD30-binding moieties and CARs, compositions comprising CD30-binding moieties and CARs, genetically modified immune cells having a chimeric antigen receptor for use in adoptive cell therapy for treating CD30-expressing cancer or tumor in a subject in need thereof are also provided herein.
-
公开(公告)号：US20220135687A1
公开(公告)日：2022-05-05
申请号：US15733313
申请日：2018-12-28
发明人： Shuai Yang , Chuan-Chu Chou , Shu Wu , Liusong Yin , Feng Lin
摘要： The present application provides an antibody, such as a monoclonal antibody (mAb), or an antigen binding fragment thereof, that specifically recognizes PD-L1. Also provided are pharmaceutical compositions, or methods of making and using the antibody or antigen binding fragment thereof.
-
公开(公告)号：US20210070855A1
公开(公告)日：2021-03-11
申请号：US16964828
申请日：2019-01-24
发明人： Tao Zhao , Huihui Zhang , Shuai Yang , Yun Zhang , Chuan-Chu Chou , Shu Wu
摘要： Provided are antibodies including monoclonal, human, primate, rodent, mammalian, chimeric, humanized and CDR-grafted antibodies, and antigen binding fragments and antigen binding derivatives thereof. These antibodies bind to CD47 protein, particularly human CD47, modulate, e.g., inhibit, block, antagonize, neutralize or otherwise interfere with CD47 expression, activity and/or signaling, including inhibiting CD47 and SIRPa interaction; do not cause a significant level of hemagglutination of human red blood cells. These antibodies may not enhance RBC phagocytosis.
-
公开(公告)号：US10407508B2
公开(公告)日：2019-09-10
申请号：US14903156
申请日：2014-07-08
发明人： Fang Liang Zhang , Jianbing Zhang , Shu Wu
IPC分类号： A61K39/395 , C07K16/34 , C07K16/18
摘要： Novel antibodies, such as single domain antibodies (sdAbs), or fragments thereof that specifically bind a transferrin are described. Compositions, methods and systems for increasing the half-life of a target protein in a serum using an antibody or fragment thereof against a transferrin are described.
-
公开(公告)号：US20240279318A1
公开(公告)日：2024-08-22
申请号：US18560661
申请日：2022-05-31
发明人： Mingxin LI , Zhigang LI , Shuai YANG , Ming ZENG , Sujuan Wang , Lan XU , Shu Wu
IPC分类号： C07K16/18 , A61K39/00 , C07K14/705 , C07K14/725 , C07K16/28 , C12N5/0783
CPC分类号： C07K16/18 , A61K39/4611 , A61K39/4631 , A61K39/4644 , C07K14/7051 , C07K14/70521 , C07K14/70578 , C07K16/2833 , C12N5/0636 , C07K2317/22 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/622 , C07K2317/92 , C07K2319/02 , C12N2510/00
摘要： This disclosure relates to antibodies, antigen-binding fragments, protein constructs, and chimeric antigen receptors that bind to a complex comprising an AFP peptide and an MHC molecule, and the uses thereof.
-
公开(公告)号：US20240150456A1
公开(公告)日：2024-05-09
申请号：US18282696
申请日：2022-04-02
发明人： Fei XU , Ruidong Hao , Wang Zhang , Shu Wu
IPC分类号： C07K16/28 , A61K39/00 , A61P35/00 , C07K14/705 , C07K14/71 , C12N5/0783
CPC分类号： C07K16/28 , A61K39/4631 , A61K39/4637 , A61K39/464402 , A61P35/00 , C07K14/70521 , C07K14/71 , C12N5/0636 , C07K2319/03 , C12N2510/00
摘要： The present disclosure provides immune effector cells engineered to express a functional exogenous receptor such as a CAR armored with a tumor homing peptide. The immune effector cells according to the present disclosure have enhanced tumor infiltration and anti-tumor efficacy.
-
公开(公告)号：US11958903B2
公开(公告)日：2024-04-16
申请号：US17043054
申请日：2019-03-29
发明人： Wang Zhang , Shuai Yang , Shu Wu , Chuan-Chu Chou
CPC分类号： C07K16/2803 , A61P35/00 , C07K16/2818 , A61K2039/505 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/569 , C07K2317/92
摘要： The present application provides anti-LAG-3 constructs comprising a single-domain antibody (sdAb) that specifically recognizes LAG-3. Also provided are methods of making and using these constructs.
-
公开(公告)号：US11932698B2
公开(公告)日：2024-03-19
申请号：US17270970
申请日：2019-08-29
发明人： Qing Dai , Jian Liu , Shuai Yang , Kun Jiang , Yuanyuan Peng , Chen Hu , Shu Wu
IPC分类号： C07K16/28 , A61K35/17 , A61K38/00 , A61K39/00 , A61P35/00 , C07K14/705 , C07K14/71 , C07K14/725 , C07K16/30
CPC分类号： C07K16/2869 , A61K35/17 , A61P35/00 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K14/71 , C07K16/3076 , A61K38/00 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , C07K2317/24 , C07K2317/565 , C07K2317/569 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2319/02 , C07K2319/03 , C07K2319/30 , C07K2319/33
摘要： Described herein are T cells engineered to express a chimeric antigen receptor (CAR), such as an anti-mesothelin CAR alone or in combination with a follicle-stimulating hormone receptor (FSHR) binding domain and/or a dominant negative transforming growth factor-β receptor II (dnTGFβRII) for the treatment of diseases associated with mesothelin expression. Also described are T cells engineered to express a modified T cell receptor (TCR).
-
公开(公告)号：US11713353B2
公开(公告)日：2023-08-01
申请号：US16962023
申请日：2019-01-15
发明人： Yafeng Zhang , Shu Wu , Shuai Yang , Chuan-Chu Chou
CPC分类号： C07K16/2818 , A61K2039/505 , C07K2317/22 , C07K2317/24 , C07K2317/31 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/76 , C07K2317/92
摘要： Provided are constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes PD-1. Also provided are methods of making and using these constructs.
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.031 秒)
